Guarnotta V, Bianco MJ, Vigneri E, et al. - Researchers assessed the alteration in circulating serum irisin and interleukin-6 (IL-6) following 6 and 12 months of GLP-1 treatment in patients suffering from type 2 diabetes mellitus (T2DM). This study involved 85 T2DM patients inadequately controlled with insulin or other hypoglycaemic drugs who were added to dulaglutide (N°=44) and liraglutide (N°=41) treatment. Findings demonstrated that both a rise in serum circulating irisin levels and a reduction in IL-6 was brought about by additive treatment with GLP1-analogues. A correlation was found between post-treatment change in irisin and reduction in total cholesterol, while the alteration in IL-6 was shown to be correlated with a reduction in waist circumference.